Narrow Aduhelm Coverage Sparks Debate Over Viability of Future Treatments

Politico, April 9th, 2022. The Biden administration’s contentious decision to only partially cover Aduhelm could reach well beyond the world of Alzheimer’s drugs, potentially affecting efforts to develop treatments for devastating diseases. “it was a defining moment for the White House and they passed with flying colors,” said Diana Zuckerman, the president of the National Center for Health Research. It “has sent a message to industry and to patient groups, and also to the FDA, that the standards had gotten too loose.”

Read More »

FDA advisers to discuss ALS drug at Wednesday meeting

Politico, March 29, 2022. On March 30, FDA holds a highly anticipated advisory committee on neurological drugs to discuss a drug from Amylyx that aims to treat amyotrophic lateral sclerosis (ALS). Dr. Diana Zuckerman told Politico: “Did the FDA schedule an advisory committee meeting to placate patient advocates and other political pressure in the hope that the advisory committee would vote against it? Or is the FDA really considering approving it?”

Read More »

Less Adderall, More Weed

Chronicle of Higher Education, February 28, 2022: Adderall, a stimulant medication often prescribed to treat attention deficit hyperactivity disorder, has been misused as a “study drug” on college campuses for years. According to the latest available annual national study, medications such as Adderall reached a 10-year low among college students in 2020.

Read More »

High Praise, Condemnation for CMS Aduhelm Coverage Plan

Medscape Medical News, February 16, 2022: Medicare has received a key endorsement and considerable support for its plan to restrict payment for the controversial Alzheimer’s disease drug aducanumab (Aduhelm) — but also drew pleas from other groups for more generous reimbursement of the drug.

Read More »